The pathophysiologic roles of interleukin-6 in human disease

Annals of Internal Medicine

Volumn 128, Issue 2, 1998, Pages 127-137

  Papanicolaou, Dimitris A ^a   Wilder, Ronald L ^b   Manolagas, Stavros C ^c   Chrousos, George P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STEROID;

ACUTE PHASE RESPONSE; BONE DISEASE; BONE REMODELING; CONFERENCE PAPER; ENDOCRINE FUNCTION; HOST RESISTANCE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LIPID METABOLISM; METABOLIC REGULATION; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; WITHDRAWAL SYNDROME;

EID: 0031963046     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-2-199801150-00009     Document Type: Conference Paper

References (115)

1. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-6.
2. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-53.
3. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75:40-7.
4. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-36.
5. Lyson K, McCann SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology. 1991;54:262-6.
6. Vankelecom H, Carmeliet P, Van Damme J, Billiau A, Denef C Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology. 1989;49:102-6.
7. Boockfor FR, Wang D, Lin T, Nagpal ML, Spangelo BL. Interleukin-6 secretion from rat Leydig cells in culture. Endocrinology. 1994;134:2150-5.
8. McGee DW, Beagley KW, Aicher WK, McGhee JR. Transforming growth factor-beta and IL-1 beta act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. J Immunol. 1993;151:970-8.
9. Kameda T, Matsuzaki N, Sawai K, Okada T, Saji F, Matsuda T, et al. Production of interleukin-6 by normal human trophoblast. Placenta. 1990; 11:205-13.
10. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990; 85:731-8.
11. Yang YC, Tsai S, Wong GG, Clark SC. Interleukin-1 regulation of hematopoietic growth factor production by human stromal fibroblasts. J Cell Physiol. 1988;134:292-6.
12. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest. 1996;97:431-7.
13. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-54.
14. Sehgal PB. Regulation of IL6 gene expression. Res Immunol. 1992;143:724-34.
15. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A. 1993;90:10193-7.
16. Akira S, Isshiki H, Nakajima T, Kinoshita S, Nishio Y, Hashimoto S, et al. A nuclear factor for the IL-6 gene (NF-IL6). Chem Immunol. 1992;51:299-322.
17. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994; 76:253-62.
18. Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. Cell. 1993;74:587-90.
19. Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S, Mori K, et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun. 1988;155: 1459-63.
20. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997;66:54-62.
21. Papanicolaou DA, Tsigos C, Torpy DJ, Defensor R, Thompson B, Chrousos GP. Recombinant interleukin-6 effects on pituitary secretion in humans [Abstract]. J Invest Med. 1996;44:A266.
22. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690-4.
23. Breuninger LM, Dempsey WL, Uhl J, Murasko DM. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 1993;69: 205-14.
24. Rock CS, Coyle SM, Keogh CV, Lazarus DD, Hawes AS, Leskiw M, et al. Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery. 1992;112:467-74.
25. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 1996;271(3 Pt 1):E601-5.
26. Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab. 1996;81:2303-6.
27. Rothwell NJ. Cytokines and thermogenesis. Int J Obes Relat Metab Disord. 1993;17(Suppl 3):S98-S101, S115.
28. Rothwell NJ. CNS regulation of thermogenesis. Crit Rev Neurobiol. 1994; 8:1-10.
29. Amatruda TT Jr, Hurst MM, D'Esopo ND. Certain endocrine and metabolic facets of the steroid withdrawal syndrome. J Clin Endocrinol Metab. 1965;25:1207-17.
30. Papanicolaou DA. Cytokines and adrenal insufficiency. Curr Opin Endocrinol Metab. 1997;4:194-8.
31. Baylis PH, Thompson CJ. Syndrome of inappropriate antidiuresis. In: Becker KL, Bilezikian JP, Bremner WJ, et al, eds. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott; 1990:241-7.
32. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994;79:934-9.
33. Felten DL, Felten SY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985;135: 755s-65s.
34. Vizi ES, Orso E, Osipenko ON, Hasko G, Elenkov IJ. Neurochemical, electrophysiological and immunocytochemical evidence for a noradrenergic link between the sympathetic nervous system and thymocytes. Neuroscience. 1995;68:1263-76.
35. van Gool J, van Vugt H, Helle M, Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol. 1990;57:200-10.
36. Soszynski D, Kozak W, Conn CA, Rudolph K, Kluger MJ. Beta-adrenoceptor antagonists suppress elevation in body temperature and increase in plasma IL-6 in rats exposed to open field. Neuroendocrinology. 1996;63: 459-67.
37. Pelton GH, Price LH, Heninger GR. Epinephrine stimulates increased IL-6 blood levels in major depression [Abstract]. Proceedings of the Annual Meeting of the American College of Neuropsychopharmacology. 1995;122.
38. Papanicolaou DA, Tsigos C, Torpy DJ, Defensor R, Thompson B, Chrousos GP. Serial fasting lipid profile changes after a single injection of interleukin-6 in normal volunteers [Abstract]. 10th International Congress of Endocrinology (ICE '96), 12-15 June 1996, San Francisco, USA. Bethesda, MD: Endocrine Soc Pr; 1996:346.
39. Brugada R, Wenger NK, Jacobson TA, Clark WS, Cotsonis G, Iglesias A. Changes in plasma cholesterol levels after hospitalization for acute coronary events. Cardiology. 1996;87:194-9.
40. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev. 1982;3:164-217.
41. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM. Association between serum interleukin-6 and serum 3,5,3-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab. 1993;77:1695-9.
42. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989;86:7547-51.
43. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992;11:587-92.
44. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183:1399-406.
45. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A. 1993;90:10061-5.
46. Libert C, Takahashi N, Cauwels A, Brouckaert P, Bluethmann H, Fiers W. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol. 1994;24:2237-42.
47. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994;180:1243-50.
48. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13:1189-96.
49. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339-42.
50. Kopf M, Ramsay A, Brombacher F, Baumann H, Freer G, Galanos C, et al. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann N Y Acad Sci. 1995;762:308-18.
51. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995;95:2886-95.
52. Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun. 1995;63:2262-8.
53. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990;86:592-9.
54. Gauldie J, Richards C, Baumann H. IL6 and the acute phase reaction. Res Immunol. 1992;143:755-9.
55. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157:473-9.
56. Culley FJ, Harris RA, Kaye PM, McAdam KP, Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol. 1996;156:4691-6.
57. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88-95.
58. Miyasaka N, Sato K, Hashimoto J, Kohsaka H, Yamamoto K, Goto M, et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol. 1989;52:238-47.
59. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis. 1995;54:674-7.
60. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988;18:1797-801.
61. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993;20: 259-62.
62. Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, et al. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol. 1994;21: 830-5.
63. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31: 784-8.
64. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerne PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol. 1993;20:815-21.
65. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol. 1995;13:307-38.
66. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the etiopathogenesis of rheumatoid arthritis J Rheumatol. 1996;23:10-2.
67. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clim Endocrinol Metab. 1997;82:1279-83.
68. Masi AT, Chrousos GP. Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis. 1997;56:1-4.
69. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992;63:10-2.
70. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147:117-23.
71. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992;90:106-10.
72. Swaak AJ, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989;8:263-8.
73. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-11.
74. Manolagas SC, Jilka RL, Bellido T, O'Brien CA, Parfitt AM. Interleukin-6 type cytokines and their receptors In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego: Academic Pr; 1996:701-13.
75. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883-91.
76. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas SC. 17 beta-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994,93:944-50.
77. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem. 1994;269:12940-6.
78. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol. 1995; 15:4971-9.
79. Passeri G, Girasole G, Jilka RL, Manolagas SC. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 1993;133:822-8.
80. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88-91.
81. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-24.
82. Lin SC, Yamate T, Taguchi Y, Borba VZ, Girasole G, O'Brien CA, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 1997;100:S160.
83. Girasole G, Pedrazzoni M, Giuliani N, Passeri G, Passeri M. Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement and reversed by alendronate administration [Abstract]. J Bone Miner Res. 1995;10:S160.
84. Chen JT, Maruo N, Kato T, Hasumi E, Ogata E, Shiraki M, et al. Serum level of soluble interleukin-6 receptor, not interleukin-6, is correlated with bone resorption markers and lumbar bone mineral density after menopause [Abstract]. J Bone Miner Res, 1996;10:S347.
85. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3450-4.
86. Rusinko R, Yin JJ, Yee J, Saad T, Mundy GR, Guise TA. Parathyroid hormone (PTH) excess is associated with increased interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6r) production [Abstract]. J Bone Miner Res. 1995; 10:S500.
87. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992;89:46-52.
88. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78:1198-204.
89. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93: 2114-9.
90. Devlin RD, Bone HG 3d, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996;81:1893-7.
91. Lakatos P, Kiss L, Tatrai A, Foldes J, Tarjan G, Stern PH. Serum IL-6 levels and bone mineral content in patients with hyper- and hypothyroidism [Abstract]. J Bone Miner Res. 1994;9:S139.
92. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab. 1996;81: 2976-9.
93. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, et al. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest. 1996;98:30-5.
94. Langub MC Jr, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 1996;50:515-20.
95. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-62.
96. Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia: Saunders; 1997:135-219.
97. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians. 1996;108:374-81.
98. Donald RA, Bailey RR, Hart D, Livesey JH, Evans MJ, Mattioli L, et al. The plasma interleukin-6 and stress hormone responses to acute pyelonephritis. J Endocrinol Invest. 1994;17:263-8.
99. Wortel CH, van Deventer SJ, Aarden LA, Lygidakis NJ, Buller HR, Hoek FJ, et al. Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery. 1993;114:564-70.
100. Drenth JP, Van Uum SH, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JW. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol. 1995;79:1497-503.
101. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994;15:771-2.
102. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993;12:225-30.
103. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52:M201-8.
104. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82: 1313-6.
105. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
106. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:982-4.
107. Perrella O, Carrieri PB, Guarnaccia D, Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J Neurol. 1992;239:387-8.
108. Merrill JE, Chen IS. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J. 1991;5:2391-7.
109. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993;629:245-52.
110. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991;285:111-4.
111. Papanicolaou DA, Torpy DJ, Tsigos C, Defensor R, Thompson B, Chrousos GP. Blunted responses of plasma ACTH and cortisol to a single injection of interleukin-6 (IL-6) in patients with Cushing syndrome. Potential diagnostic use of the IL-6 [Abstract]. 10th International Congress of Endocrinology, 12-15 June 1996, San Francisco, USA. Bethesda, MD: Endocrine Soc Pr; 1996:901.
112. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993;269:2232-8.
113. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995;771:716-29.
114. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583-92.
115. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991;73:1224-34.